Search results
Showing results for
Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The funding will enable the company to build its clinical pipeline and grow its proprietary unique antibody dataset to more than a billion sequences.
Moa announces Series C funding round
22 July 2026
Moa Technology (“Moa”), an agricultural biotechnology company focused on discovering novel mode of action herbicides, announces a £22.2 million Series C financing round, co-led by Oxford Science Enterprises (“OSE”) and Supernova Invest (“Supernova”).
Oxford Cancer Analytics joins major collaborative study to transform lung cancer screening in the UK
20 July 2026
Thousands of people in Cheshire and Merseyside are being invited to take part in pioneering Liverpool-led research that could shape the future of lung cancer screening.
Theolytics announces that it has relocated to new, state‑of‑the‑art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world‑class research institutes, teaching hospitals and university
15 July 2026
Theolytics, a clinical‑stage biotechnology company developing next‑generation oncolytic immunotherapies, announces that it has relocated to new, state‑of‑the‑art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world‑class research institutes, teaching hospitals and university. The company joins a thriving community of more than 30 science and technology companies at ARC Oxford, further strengthening the campus’ position as a hub for cutting‑edge innovation.
Alchemab Therapeutics announce biggest ever life sciences investment from British Business Bank to advance its AI-enabled clinical pipeline of next generation human-derived antibodies
8 July 2026
Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The funding will enable the company to build its clinical pipeline and grow its proprietary unique antibody dataset to more than a billion sequences.
Moa and Corteva sign collaboration deal
6 July 2026
Moa Technology and Corteva collaborate to accelerate discovery of novel herbicides
Theolytics’ ongoing US phase 1 OCTOPOD-IP trial of THEO-260 in ovarian cancer to be presented as a trial in progress at ASCO 2026
27 May 2026
THEO-260 is an oncolytic immunotherapy designed to effectively target cancer cells and cancer-associated fibroblasts while inducing immune activation in stroma-rich tumours. The US trial (OCTOPOD-IP) is exploring the safety and tolerability of intraperitoneal delivery of THEO-260 in high-grade serous or endometroid ovarian cancer.
Theolytics announces first patient dosed in the OCTOPOD-IP Trial, a US phase 1 trial with THEO-260, a novel oncolytic immunotherapy targeting ovarian cancer
27 April 2026
Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating intraperitoneal (IP) administration of THEO-260 for the treatment of women with Platinum-Resistant Ovarian Cancer (PROC) (NCT07211659).
Enara Bio presents first-in-class DARKFOX-Targeting bispecific T Cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential in solid tumour immunotherapy
19 April 2026
ENA101 targets DARKFOX®, a novel, cancer‑specific Dark Antigen encoded by a previously undiscovered alternative open reading frame (alt‑ORF) within FOXM1. DARKFOX was discovered and validated using Enara’s proprietary EDAPT® platform and represents a new class of highly tumour-specific targets derived from the dark proteome.
Alethio Therapeutics unveils ATX‑011, a breakthrough, mutation‑agnostic antibody for treating essential thrombocythemia – a c.$2B market, and strengthens leadership to accelerate path to IND
15 April 2026
Alethio Therapeutics, a biopharmaceutical company developing novel treatments for myeloproliferative neoplasms (MPN), today announced the unveiling of ATX‑011, a first‑in‑class, mutation‑agnostic antibody with potential to disrupt the $2B Essential Thrombocythemia (ET) market. Alongside this, the Company announces the appointment of Steve R. Coats, PhD, a veteran biologics leader, as Chief Development Officer, to advance the ATX-011 programme towards IND submission, targeted for Q1 2027.
Bioarchitech secures strategic material license with the UK Health Security Agency (UKHSA) to support manufacturing and clinical development of BA-V151
29 March 2026
Bioarchitech, Oxford, UK, an immuno-oncology therapeutics start-up company announces that it has secured a material license from the European Collection of Authenticated Cell Cultures (ECACC), UKHSA for a mammalian cell line to be developed as a scalable and high yield viral manufacturing platform and for the vector backbone of BA-V151, a preclinical stage candidate being developed as a treatment for metastatic cancers.
PepGen announces topline results from lowest dose (5 mg/kg) MAD cohort in the ongoing phase 2 FREEDOM2 study demonstrating favourable safety, splicing and vHOT data
29 March 2026
PGN-EDODM1 was generally well-tolerated, with all adverse events being mild or moderate, and no serious adverse events reported. The mean splicing correction observed with PGN-EDODM1 (n=6) was 7.3%, compared to 6.8% for the placebo (n=2). Excluding one outlier patient, the treatment group showed a mean splicing correction of 22.9% (n=5). Promising trends were seen in vHOT in the PGN-EDODM1 treated group. The company is on track to report clinical data from the 10 mg/kg multiple dose cohort in the second half of 2026, with sufficient cash expected to fund operations into the second half of 2027.
Enara Bio to unveil first-in-class DARKFOX-targeting bispecific T cell engager ENA101 in oral presentation at AACR 2026, showcasing breakthrough potential for solid tumour immunotherapy
18 March 2026
Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager innovation, today announced new data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, highlighting its lead clinical candidate, ENA101, a first-in-class bispecific T cell engager (TCE) targeting DARKFOX®, a novel cancer-specific Dark Antigen discovered with Enara’s EDAPT® platform.
Let’s just get married – the story of an acquisition
5 March 2026
"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.
Theolytics awarded €8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer
4 March 2026
Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.
CyanoCapture and Persist AI announce strategic collaboration to build world's first robotic GMP facility for oral protein and peptide drugs
18 February 2026
The pioneering partnership combines cyanobacteria-based oral delivery with AI-driven robotics to transform how life-saving biologics reach patients.
Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer
16 February 2026
Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment reflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.
OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors
28 January 2026
OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.
Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies
8 January 2026
Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara’s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara’s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.
Certis Belchim and Moa sign strategic collaboration deal
8 January 2026
Netherlands-based company becomes Moa's third major commercial partner in 18 months.
Nucleome Therapeutics nominates first preclinical development candidate
7 January 2026
First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.